As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: May 30, 2012
by Michelle Henderson for Nine News:
Powerful new imaging technology will play a role in the largest-ever disease prevention trial in Australia.
The ASPREE (ASPirin in Reducing Events in the Elderly) study is investigating the risks and benefits of aspirin in healthy people over 70. The study involving 15,000 Australians and 4,000 people from the US hopes to discover whether a daily low dose of aspirin could help elderly people live well for longer.
New imaging technology at Monash Biomedical Imaging, which officially opened in Melbourne on Wednesday, will be used to undertake a second study associated with the larger trial. Prof John McNeil, head of the School of Public Health and Preventive Medicine at Monash University, said the technology now available would help researchers understand how aspirin works on the brain and carotid arteries.
The imaging would enable researchers to observe the thickening of the carotid arteries, the main blood vessels leading to the brain, he said.
Prof McNeil said the technology, including a more powerful Magnetic Resonance Imaging (MRI) scanner, could also help scientists understand the effect of aspirin on strokes.
About 1,000 people among the 6,500 Australians who have been recruited to the larger trial have volunteered to undergo imaging.
Prof McNeil said he hoped a further 500 would volunteer. The brain imaging study will get underway in September.
A low dose of aspirin is known to reduce the risk of secondary heart attack or stroke, but is can also have adverse effects such as increased bleeding.
A Danish study published this week found aspirin was linked to a reduced risk of some skin cancers, melanoma and squamous cell carcinoma.
A new comprehensive study from Florida State University (FSU) finds no evidence to support the idea that personality changes begin before the clinical onset of mild cognitive impairment (MCI) or dementia. MCI is an intermediate...
On the evening of Monday November 27th, join us for conversation and cocktails with award-winning journalist, editor and author Tina Brown, and Indigo’s CEO Heather Reisman. Hear from Tina Brown about her eight-year tenure at Vanity...
The presence of TAR DNA-binding protein 43 (TDP-43) in the hippocampus on postmortem examination is associated with increased rates of hippocampal atrophy in patients with Alzheimer’s disease (AD), new research suggests. This association was greatest...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.